VivoSeq
Oncology

Breast Carcinoma in Situ

6

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Breast Carcinoma in Situ is an early-stage landscape with 6 programs across 4 companies. The most active players are San Diego Pacific Oncology & Hematology Associates, Merck & Co., Pfizer. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

San Diego Pacific Oncology & Hematology Associates

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 3Pfizer logo

Pfizer

1 program

ApprovedNovartis logo

Novartis

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

4 of 6 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody233%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Completed·National Cancer Institute (NCI)·N/A·NCT00555152·22 enrolled
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
Completed·NNorthwestern University·Phase 2·NCT00952731·27 enrolled
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02954874·1,155 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)